These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19446431)

  • 1. [Drug treatment for hypertrophic cardiomyopathy].
    Gibelin P
    Presse Med; 2009 Jun; 38(6):1001-4. PubMed ID: 19446431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with β-blockade or verapamil.
    Sherrid MV; Shetty A; Winson G; Kim B; Musat D; Alviar CL; Homel P; Balaram SK; Swistel DG
    Circ Heart Fail; 2013 Jul; 6(4):694-702. PubMed ID: 23704138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug.
    Verlinden NJ; Coons JC
    Pharmacotherapy; 2015 Dec; 35(12):1164-72. PubMed ID: 26684556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy.
    Sherrid MV; Barac I; McKenna WJ; Elliott PM; Dickie S; Chojnowska L; Casey S; Maron BJ
    J Am Coll Cardiol; 2005 Apr; 45(8):1251-8. PubMed ID: 15837258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives.
    Ammirati E; Contri R; Coppini R; Cecchi F; Frigerio M; Olivotto I
    Eur J Heart Fail; 2016 Sep; 18(9):1106-18. PubMed ID: 27109894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic obstructive hypertrophic cardiomyopathy.
    Sorajja P; Ommen SR; Nishimura RA
    Circ Cardiovasc Interv; 2013 Oct; 6(5):586-91. PubMed ID: 24129935
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
    Kajimoto K; Imai T; Minami Y; Kasanuki H
    Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypertrophic cardiomyopathy: place and limitations of medical therapy].
    Desnos M; Hagège A; Guérot C
    Arch Mal Coeur Vaiss; 1995 Apr; 88(4 Suppl):573-5. PubMed ID: 7487302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heart failure associated with hypertrophic cardiomyopathy].
    Oka N; Ohmura H; Ueda T
    Nihon Rinsho; 2007 May; 65 Suppl 5():425-9. PubMed ID: 17569322
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death.
    Ostman-Smith I
    Fundam Clin Pharmacol; 2010 Oct; 24(5):637-52. PubMed ID: 20727015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of hypertrophic cardiomyopathy: relation to pathological mechanisms.
    Kaltenbach M; Hopf R
    J Mol Cell Cardiol; 1985 Jul; 17 Suppl 2():59-68. PubMed ID: 4040978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of hypertrophic cardiomyopathy determines its medical treatment.
    Musat D; Sherrid MV
    Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():9-17. PubMed ID: 17162264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertrophic cardiomyopathy. Combination of beta blockers and verapamil may be risky.
    Borja J; Izquierdo I; Guindo J
    BMJ; 2006 Jul; 333(7558):97. PubMed ID: 16825239
    [No Abstract]   [Full Text] [Related]  

  • 14. The management of hypertrophic cardiomyopathy.
    Spirito P; Seidman CE; McKenna WJ; Maron BJ
    N Engl J Med; 1997 Mar; 336(11):775-85. PubMed ID: 9052657
    [No Abstract]   [Full Text] [Related]  

  • 15. [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
    McKenna WJ; Kleinebenne A
    Herz; 1985 Apr; 10(2):91-101. PubMed ID: 2580767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug treatment of hypertrophic cardiomyopathy].
    Hirzel HO
    Herz; 1985 Apr; 10(2):84-90. PubMed ID: 4039293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Beneficial effects of disopyramide on left ventricular outflow obstruction in a case of hypertrophic obstructive cardiomyopathy].
    Terrosu P; Franceschino V; Contini GM; Dore L; Ibba GV
    G Ital Cardiol; 1984 Jan; 14(1):63-6. PubMed ID: 6538527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy.
    Melacini P; Maron BJ; Bobbo F; Basso C; Tokajuk B; Zucchetto M; Thiene G; Iliceto S
    Heart; 2007 Jun; 93(6):708-10. PubMed ID: 17502652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in medical treatment of hypertrophic cardiomyopathy.
    Hamada M; Ikeda S; Shigematsu Y
    J Cardiol; 2014 Jul; 64(1):1-10. PubMed ID: 24735741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of hypertrophic cardiomyopathy].
    Cecchi F; Olivotto I
    G Ital Cardiol; 1999 Oct; 29(10):1199-203. PubMed ID: 10546134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.